Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programmeRuth E. Langley, Mahesh Parmar, Matthew Nankivell et al.|The Lancet|2021Cited by 49
Patients’ Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER StudyMartin J. Connor, Verity Watson, Mesfin G. Genie et al.|European Urology Oncology|2024Cited by 4